ATHEROSCLEROSIS--INHIBITING THE SCAVENGER RECEPTOR GENE

Information

  • Research Project
  • 2223084
  • ApplicationId
    2223084
  • Core Project Number
    R44HL046623
  • Full Project Number
    5R44HL046623-03
  • Serial Number
    46623
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/1991 - 33 years ago
  • Project End Date
    2/29/1996 - 28 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1994 - 30 years ago
  • Budget End Date
    2/29/1996 - 28 years ago
  • Fiscal Year
    1994
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/24/1994 - 30 years ago

ATHEROSCLEROSIS--INHIBITING THE SCAVENGER RECEPTOR GENE

Atherosclerotic lesions develop from fatty streaks in the intimal layer of arteries and are characterized by accumulation of cholesterol laden foam cells. Macrophages convert to foam cells by the uncontrolled accumulation of oxidized LDL, taken up via the scavenger receptor. Drugs specifically inhibiting this receptor could halt plaque progression, presenting a novel approach in treating atherosclerosis. The ultimate objective of this project is the discovery of small molecule inhibitors of scavenger receptor transcription by screening over 100,000 chemicals using our proprietary robotics in a high-throughput screen. In Phase I 4.5kb of 5' flanking region of the scavenger receptor gene was used to prepare promoter-luciferase reporter constructs. As a control, the LDLr promoter was synthesized by PCR and a promoter luciferase reporter vector constructed. In Phase II, stable cell lines containing the scavenger receptor.luciferase reporter will be isolated and the high-throughput screen initiated. In parallel, to ensure all regulatory transcription sequences are obtained, we will generate a second reporter construct, designed for integration at the site of scavenger receptor locus in the genome. Lead compounds will be evaluated in secondary assays by quantitative PCR and their ability to inhibit the accumulation of oxidized LDL by macrophages.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    OSI PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    UNIONDALE
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    11553
  • Organization District
    UNITED STATES